...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biomarker Research >Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
【24h】

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia

机译：Gemtuzumab ozogamicin和新型抗体 - 药物缀合物在急性髓细胞白血病的临床试验中

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for induction therapy of AML. When used in fractionated doses, GO combined with the conventional cytarabine/anthracycline-based induction chemotherapy significantly improves the outcome of previously untreated AML patients. Single-agent GO is effective and safe for AML patient ineligible for intensive chemotherapy. Multiple combination regimens incorporating GO have also been recommended as potential alternative options. In addition, several novel ADCs targeting CD33, CD123 and CLL-1 are currently undergoing preclinical or early clinical investigations. In this review, we summarized the efficacy and limitations of GO as well as novel ADCs for adult AML patients.? The Author(s). 2019.
机译：靶向剂越来越多地用于急性髓性白血病（AML）的治疗。 Gemtuzumab ozogamicin（Go）是批准的第一抗体 - 药物缀合物（ADC），用于诱导AML的诱导治疗。当以分馏剂量使用时，与常规的含有含有含有的含有含有的含有含有的含有含有的含有术的血糖素的诱导化疗。单体代理商GO是有效的，可安全地为AML患者不符合强化化疗。还有多个组合的方案，也建议了潜在的替代选项。此外，靶向CD33，CD123和CLL-1的几种新型ADC目前正在进行临床前或早期的临床研究。在这篇综述中，我们总结了成人AML患者的GO和新型ADC的疗效和局限性。作者。 2019年。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号